


**ASX: ALA**

Arovella Therapeutics Limited  
ACN 090 987 250

**ASX RELEASE**

8 May 2025

**RESULTS OF GENERAL MEETING**

**MELBOURNE, AUSTRALIA 8 May 2025:** Arovella Therapeutics, (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform, advises that all resolutions considered at the Extraordinary General Meeting held today were carried by poll.

In accordance with ASX Listing rule 3.13.2 and Section 251AA of the Corporations Act 2001, details of the proxies received and votes cast in respect of each resolution are attached.

**Tim Luscombe**  
**Company Secretary**  
**Arovella Therapeutics Limited**

# Disclosure of Proxy Votes

Arovella Therapeutics Limited

Extraordinary General Meeting

Thursday, 08 May 2025



GPO Box 5193, Sydney, NSW 2001  
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)  
F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)  
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Ratification of issue of Placement Shares	P	44,033,596	40,629,097 92.27%	2,444,995 5.55%	1,692,137	959,504 2.18%	41,588,601 94.45%	2,444,995 5.55%	1,692,137	Carried
2 Ratification of issue of Placement Options	P	44,033,516	40,481,799 91.93%	2,592,213 5.89%	1,692,217	959,504 2.18%	41,441,303 94.11%	2,592,213 5.89%	1,692,217	Carried

